基于40年经验制定的鼻整形患者围手术期过度出血与瘀斑控制算法
基于一位资深作者43年经验制定的术中出血管理算法,回顾性分析103例连续鼻中隔鼻整形患者。26例(25.2%)未用止血剂,26例(25.2%)仅用氨甲环酸,3例(2.91%)仅用去氨加压素,1例(0.97%)仅用维生素K,46例(44.7%)联用氨甲环酸和去氨加压素,1例(0.97%)三者联用。所有患者术中出血均得到控制,无术后鼻出血、血栓栓塞等并发症。
要点
- 103例鼻中隔鼻整形患者中,46例(44.7%)需联用氨甲环酸和去氨加压素控制出血。
- 术中出血控制方案:先静脉给予氨甲环酸10 mg/kg,必要时去氨加压素最大剂量0.3 µg,仍出血则加维生素K 10 mg。
- 已知I型或IIa型血管性血友病患者术前接受去氨加压素;无术后鼻出血或血栓栓塞发生。
核心结论
- 氨甲环酸、去氨加压素和维生素K组成的算法可有效控制术中过度出血、术后瘀斑和鼻出血。
研究设计与样本
- 回顾性病历审查,纳入103例由单一术者连续行鼻中隔鼻整形术的患者。
- 由资深作者基于43年经验制定术中出血管理算法。
主要发现
- 26例(25.2%)未接受术中止血剂;26例(25.2%)仅需氨甲环酸;3例(2.91%)仅给去氨加压素;1例(0.97%)仅给维生素K;46例(44.7%)需氨甲环酸和去氨加压素联用;1例(0.97%)需氨甲环酸、去氨加压素和维生素K三者联用。
- 所有患者术中出血均得到控制;1例已知因子11缺乏患者术中接受氨甲环酸和去氨加压素但无需新鲜冰冻血浆。
- 无患者发生术后鼻出血、血栓栓塞或其他相关并发症。
关键数值与推荐
- 术中出血控制顺序:首先静脉给予氨甲环酸10 mg/kg,必要时给予去氨加压素最大剂量0.3 µg,若出血持续则给予维生素K 10 mg。
- 已知I型或IIa型血管性血友病患者术前接受去氨加压素。
临床怎么用
- 作者采用基于经验的算法:先静脉氨甲环酸10 mg/kg,必要时去氨加压素最大0.3 µg,持续出血加维生素K 10 mg。
- 已知I型或IIa型血管性血友病患者术前给予去氨加压素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Persistent intraoperative bleeding, excessive postoperative ecchymosis, epistaxis, and blood collection in the supratip area increase the complexity of rhinoplasty, causing suboptimal outcomes. The authors present an intraoperative bleeding management algorithm, developed by the senior author (B.G.) based on 43 years of experience, and assess its efficacy in achieving hemostatic control through 103 consecutive cases. METHODS: A retrospective chart review was conducted on 103 consecutive patients who had undergone septorhinoplasty performed by a single surgeon. The authors reviewed patient demographics; coagulopathies; medications; diet; intraoperative use of tranexamic acid (TXA), deamino-8- d -arginine vasopressin (DDAVP), and vitamin K; and postoperative complications. RESULTS: Twenty-six patients (25.2%) did not receive intraoperative hemostatic agents. Twenty-six patients (25.2%) required TXA only, 3 patients (2.91%) were given DDAVP only, 1 patient (0.97%) received vitamin K only, and 46 patients (44.7%) required both TXA and DDAVP. One patient (0.97%) needed TXA, DDAVP, and vitamin K. Intraoperative bleeding was controlled in all patients. One patient with known factor 11 deficiency received both TXA and DDAVP intraoperatively but did not require fresh frozen plasma. Intraoperative bleeding was controlled by first administering 10 mg/kg of TXA intravenously, followed by DDAVP with a maximum dose of 0.3 µg if needed, and 10 mg of vitamin K if bleeding persisted. Patients with known type I or IIa von Willebrand disease received DDAVP preoperatively. No patient experienced postoperative epistaxis, thromboembolism, or other associated complications. CONCLUSION: The algorithm of TXA, DDAVP, and vitamin K is effective in controlling excessive intraoperative bleeding, postoperative ecchymosis, and epistaxis. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
引用
- Guyuron B, Cakmakoglu C, Avasarala V, et al. An Algorithm for Control of Excessive Perioperative Bleeding and Ecchymosis in Rhinoplasty Patients Based on 4 Decades of Experience. Plast Reconstr Surg. 2024. PMID: 38589989. doi:10.1097/PRS.0000000000011462
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。